WO2004081224A2 - Reca-assisted allele specific oligonucleotide extension method - Google Patents
Reca-assisted allele specific oligonucleotide extension method Download PDFInfo
- Publication number
- WO2004081224A2 WO2004081224A2 PCT/US2004/006704 US2004006704W WO2004081224A2 WO 2004081224 A2 WO2004081224 A2 WO 2004081224A2 US 2004006704 W US2004006704 W US 2004006704W WO 2004081224 A2 WO2004081224 A2 WO 2004081224A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dna
- reca
- probe
- oligonucleotide
- specific
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 title claims abstract description 84
- 238000000034 method Methods 0.000 title claims abstract description 57
- 108700028369 Alleles Proteins 0.000 title claims abstract description 24
- 101100355584 Mus musculus Rad51 gene Proteins 0.000 title 1
- 108010055016 Rec A Recombinases Proteins 0.000 claims abstract description 116
- 102000001218 Rec A Recombinases Human genes 0.000 claims abstract description 115
- 239000000523 sample Substances 0.000 claims abstract description 79
- 230000035772 mutation Effects 0.000 claims abstract description 62
- 230000000295 complement effect Effects 0.000 claims abstract description 42
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 28
- 239000002773 nucleotide Substances 0.000 claims abstract description 26
- 108020004414 DNA Proteins 0.000 claims description 133
- 102000053602 DNA Human genes 0.000 claims description 29
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 21
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 21
- 230000003321 amplification Effects 0.000 claims description 16
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 16
- 239000012634 fragment Substances 0.000 claims description 14
- 241000588724 Escherichia coli Species 0.000 claims description 13
- 239000013612 plasmid Substances 0.000 claims description 13
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 8
- 101710176276 SSB protein Proteins 0.000 claims description 4
- 101710126859 Single-stranded DNA-binding protein Proteins 0.000 claims description 4
- 229960002685 biotin Drugs 0.000 claims description 4
- 235000020958 biotin Nutrition 0.000 claims description 4
- 239000011616 biotin Substances 0.000 claims description 4
- 230000002285 radioactive effect Effects 0.000 claims description 4
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 claims description 3
- 108020005202 Viral DNA Proteins 0.000 claims description 3
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 claims description 3
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 claims description 3
- 238000000684 flow cytometry Methods 0.000 claims description 2
- 230000000890 antigenic effect Effects 0.000 claims 2
- 230000002255 enzymatic effect Effects 0.000 claims 2
- 239000002299 complementary DNA Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 abstract description 20
- 108020005187 Oligonucleotide Probes Proteins 0.000 abstract description 9
- 239000002751 oligonucleotide probe Substances 0.000 abstract description 9
- 102000054765 polymorphisms of proteins Human genes 0.000 abstract description 6
- 230000008569 process Effects 0.000 abstract description 5
- 239000000203 mixture Substances 0.000 abstract description 3
- 102000018120 Recombinases Human genes 0.000 abstract 1
- 108010091086 Recombinases Proteins 0.000 abstract 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 34
- 238000001514 detection method Methods 0.000 description 31
- 108090000623 proteins and genes Proteins 0.000 description 30
- 238000003752 polymerase chain reaction Methods 0.000 description 27
- 102000004169 proteins and genes Human genes 0.000 description 18
- 239000003153 chemical reaction reagent Substances 0.000 description 11
- 230000006798 recombination Effects 0.000 description 10
- 108020004682 Single-Stranded DNA Proteins 0.000 description 9
- 230000027455 binding Effects 0.000 description 9
- 238000003556 assay Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 108091093088 Amplicon Proteins 0.000 description 7
- 238000004925 denaturation Methods 0.000 description 7
- 230000036425 denaturation Effects 0.000 description 7
- 238000005215 recombination Methods 0.000 description 7
- 239000003298 DNA probe Substances 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 108091008146 restriction endonucleases Proteins 0.000 description 6
- 238000012408 PCR amplification Methods 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 238000000137 annealing Methods 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 241000894007 species Species 0.000 description 5
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 4
- 241000801924 Sena Species 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 230000004568 DNA-binding Effects 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 238000003205 genotyping method Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 238000002493 microarray Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000219 mutagenic Toxicity 0.000 description 3
- 230000003505 mutagenic effect Effects 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- WCKQPPQRFNHPRJ-UHFFFAOYSA-N 4-[[4-(dimethylamino)phenyl]diazenyl]benzoic acid Chemical compound C1=CC(N(C)C)=CC=C1N=NC1=CC=C(C(O)=O)C=C1 WCKQPPQRFNHPRJ-UHFFFAOYSA-N 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 102000004420 Creatine Kinase Human genes 0.000 description 2
- 108010042126 Creatine kinase Proteins 0.000 description 2
- 108020003215 DNA Probes Proteins 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 108010004469 allophycocyanin Proteins 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- -1 deoxyribonucleotide triphosphates Chemical class 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 230000003100 immobilizing effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- DLBFLQKQABVKGT-UHFFFAOYSA-L lucifer yellow dye Chemical compound [Li+].[Li+].[O-]S(=O)(=O)C1=CC(C(N(C(=O)NN)C2=O)=O)=C3C2=CC(S([O-])(=O)=O)=CC3=C1N DLBFLQKQABVKGT-UHFFFAOYSA-L 0.000 description 2
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 230000033607 mismatch repair Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229950007002 phosphocreatine Drugs 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- WGTODYJZXSJIAG-UHFFFAOYSA-N tetramethylrhodamine chloride Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C(O)=O WGTODYJZXSJIAG-UHFFFAOYSA-N 0.000 description 2
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 2
- 235000011178 triphosphate Nutrition 0.000 description 2
- 239000001226 triphosphate Substances 0.000 description 2
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 2
- 208000031295 Animal disease Diseases 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 102000002490 Rad51 Recombinase Human genes 0.000 description 1
- 108010068097 Rad51 Recombinase Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- NLTUCYMLOPLUHL-KQYNXXCUSA-N adenosine 5'-[gamma-thio]triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=S)[C@@H](O)[C@H]1O NLTUCYMLOPLUHL-KQYNXXCUSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 230000037429 base substitution Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
- C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
Definitions
- the present invention in the fields of molecular biology and medicine relates to methods for detecting specific sequences in double-stranded DNA samples and for detecting mutations and polymorphisms involving as little as one base change (Single Nucleotide Polymorphism - SNP) or additions to or deletions from the wild-type DNA sequence.
- the ability to detect a mutation has taken on increasing importance in early detection of cancer or discovery of susceptibility to cancer with the discovery that discrete mutations in cellular onco genes can result in activation of that oncogene leading to the transformation of that cell into a cancer cell and that mutations inactivating tumor suppressor genes are required steps in the process of tumorigenesis
- the detection of SNPs has assumed increased importance in the identification and localization (mapping) of genes, including those associated with human and animal diseases. Further, the continuing and dramatic increase in the number of SNPs of known location in the genome will allow genome wide scanning for identification of disease associated genes and help usher in the era of personalized medicine.
- PCR polymerase chain reaction
- PCR amplification is a relatively low fidelity process. Misincorporation during amplification is a particular problem in those detection methods that involve denaturation and annealing of PCR amplicons to form mutant: wild type heteroduplexes in which mutations and SNPs are revealed as mismatched or unpaired bases. Given the random nature of PCR errors, virtually all will be in such mismatches following annealing and will contribute to background signal. In gel based applications these error-containing molecules will generally not interfere. However, in high through put applications involving mismatch binding or mismatch cleaving, high background signals can greatly limit the utility of a method and frequently require that PCR fragments be kept relatively short.
- PCR is subject to mispriming.
- Mispriming involves primer extension at non- target sites, which can occur even when only a relatively short portion of the 3' end of a primer is transiently paired with some sequence in the target DNA. Mispriming can produce long single-stranded fragments which can adopt mismatch-containing secondary structure. Mispriming is also a major problem in those methods which utilize primer extension for SNP detection. These methods use oligonucleotides which are complementary to a region of target DNA immediately adjacent to the SNP or mutation to be genotyped such that the first nucleotide added by DNA polymerase to the 3' end of the oligonucleotide will be complementary to and diagnostic for the SNP.
- these methods use specific nucleotide terminators (e.g., dideoxy or acyclo nucleotides) which are detectably labeled. Mispriming is such a problem with these methods that they generally require pre-amplification of the target region.
- specific nucleotide terminators e.g., dideoxy or acyclo nucleotides
- Allele specific amplification is a method of PCR amplification that selectively amplifies only one allele of a given SNP or mutation.
- the method involves selecting one PCR primer (diagnostic primer) that is substantially complementary to the target DNA except at the 3' end where "a 3' terminal nucleotide of the diagnostic primer [is] either complementary to a suspected variant nucleotide or to the corresponding normal nucleotide.”
- An extension product is obtained only when the terminal nucleotide is complementary to the corresponding nucleotide in the target DNA sequence and is revealed by amplification using a second, amplifying primer.
- Allele specific amplification in contrast with the present invention, requires an amplification primer, denaturation of the target DNA to allow hybridization of the diagnostic and amplification primers and is clearly dependent on PCR for detection. Further, complete genotyping requires separate amplification reaction with diagnostic primers with 3' termini complementary to each of the alleles of the SNP or mutation in question. Simultaneous exposure of a target DNA sample to both diagnostic primers (in the case of a two allele SNP) will always give an amplification product and will not allow genotyping unless an additional step, such as gel electrophoresis or mass spectroscopy is included. For the products to be distinguishable, the diagnostic primers must be sufficiently different, i.e., different in length or containing different adducts, such that the amplification products can be separated and distinguished by some means. RecA
- RecA is a bacterial protein involved in DNA repair and genetic recombination and has been best characterized in E. coli. RecA is the key player in the process of genetic recombination, in particular in the search and recognition of sequence homology and the initial strand exchange process. RecA can catalyze strand exchange in the test tube. Recombination is initiated when multiple RecA molecules coat a stretch of single-stranded DNA (ssDNA) to form what is known as a RecA filament. This filament, in the presence of ATP, searches for homologous sequences in double-stranded DNA (dsDNA). When homology is located, a three stranded (D-loop) structure is formed wherein the RecA filament DNA is paired with the complementary strand of the duplex.
- ssDNA single-stranded DNA
- dsDNA double-stranded DNA
- RecA homology searching is extremely precise and RecA has been used to facilitate screening of plasmid libraries for plasmids containing specific sequences (Rigas et al, Proc Natl Acad Sci USA. 83:9591-9595 (1986)).
- biotinylated ssDNA probes are reacted with RecA to form RecA filaments.
- the filaments are used for homology searching in circular plasmid DNA.
- those plasmids containing sequences homologous to the probes are isolated by virtue of the triple stranded (D- loop) structures formed by the RecA filament and the plasmid duplex.
- ATP[ ⁇ -S] adenosine 5'-[ ⁇ -thio]triphosphate
- RecA has also been used, in a variety of applications, to facilitate the mapping and/or isolation of specific DNA regions from bacterial and human genomic DNA (Ferrin, J, et al, Science 254:1494-1497 (1991); Ferrin, LJ, et al, Nature Genetics 6:379-383 (1994); Ferrin, LJ and Camerini-Otero, RD, Proc Natl Acad Sci 95:2152-2157 (1998), Sena et al, U.S. Pat. 5,273,881 and 5,670,316; Sena and Zarling, Nature Genetics 3:365-371 (1993)).
- RecA is used in conjunction with restriction enzymes (sequence specific double strand DNA endonucleases) to allow isolation or identification of specific DNA fragments. RecA filaments are prepared and reacted with genomic DNA under conditions that allow triple strand (D-loop) structure formation.
- the DNA is then treated with either a restriction endonuclease or a modification methylase (methylase action transfers a methyl group to the specific recognition sequence of a specific restriction endonuclease, thus protecting the sequence from endonuclease digestion).
- methylase action transfers a methyl group to the specific recognition sequence of a specific restriction endonuclease, thus protecting the sequence from endonuclease digestion).
- the presence of the RecA filament in the triple strand structure prevents digestion or methylation.
- RecA filaments have been used to protect restriction endonuclease generated "sticky ends" from being filled in by DNA polymerase such that, upon removal of the RecA filaments, specific fragments can be cloned into plasmid vectors, hi this application, genomic DNA is digested with one or more restriction enzymes that produce recessed 3' ends. A specific fragment from this digestion is protected by triple strand structure formation with a pair of RecA filaments. The recessed 3' ends of the remaining fragments are then filled in with a polymerase. The polymerase is removed or inactivated, the RecA, filament is removed and the specific fragment cloned by virtue of its sticky ends.
- RecA has been used in association with DNA ligase to label specific DNA fragments (Fujiwara, J et al, Nucl Acids Res 26:5728-5733 (1998)).
- oligonucleotides are designed to allow the 3' end to form a double-stranded region by folding back on a portion of itself (hairpin), RecA is then used to coat the remaining single-stranded 3' region and the resulting RecA filament used to perform homology searching.
- ligation can covalently link the oligonucleotide, which can be labeled at the 5' end with a detectable label, to the target DNA to allow detection or isolation of specific target DNA sequences without denaturation of the target DNA.
- the present invention is directed to a RecA assisted method for detecting of a mutation and or a SNP or of a specific DNA sequence in a double-stranded target or test DNA molecule, which will hereinafter be referred to as the RecA/AlIele specific oligonucleotide extension (RecA/ASOE) method.
- the RecA/ASOE method of SNP and mutation detection comprises:
- a ssDNA probe which is optionally detectably labeled or which optionally includes an adduct at its 5' end or internally that allows immobilization, which probe has a known nucleotide sequence complementary to the sequence of at least a part of the target DNA, the sequence of which is such that, when annealed to the complementary region of the target DNA, the 3' end of the probe covers the site of the mutation or SNP and is complementary to one allele of the mutation or SNP;
- the D-loop structure comprises the probe and the two strands of the target DNA;
- dNTPs deoxyribonucleotide triphosphates
- extension depends on the correct base pairing of the 3' end of the probe with the target SNP, mutation or specific sequence
- extension i.e., the presence of the dNTPs covalently attached to the 3' end of the DNA probe.
- Extension of the probe is indicative of the presence of the specific allele of the mutation or SNP in the target DNA.
- the RecA ASOE method for detecting a specific sequence comprises: (a) providing a ssDNA probe which is optionally detectably labeled or which includes an adduct at its 5' end or internally to allow immobilization, , which probe has a known nucleotide sequence complementary to a specific DNA sequence;
- d contacting the DNA D-loop structure, in the presence dNTPs, which may optionally be detectably labeled or include an adduct which allows immobilization, with a DNA polymerase capable of primer extension under conditions wherein the oligonucleotide will be extended if and only if the 3 ' end of the oligonucleotide is correctly base paired with the target DNA;
- the probe may be any ssDNA, including, but not limited to, synthetic oligonucleotides of any length, denatured PCR amplicons and denatured restriction enzyme digestion fragments from any plasmid, viral, bacterial or eukaryotic genomic DNA. Probes are preferably synthetic oligonucleotides 20 - 120 nucleotides in length, more preferably 40 - 60 nucleotides in length.
- the RecA protein is preferably from E. coll
- the labels may be any suitable detectable label, e.g., a fluorophore, a chromophore, a radionuchde, biotin, digoxigenin, etc.
- the probe DNAs, dNTPs or terminators may be directly labeled by direct bonding or binding of the label.
- the term "detectably labeled,” includes “indirect” labeling wherein the "detectable label” is a primary antibody, or any other binding partner, which is directly labeled.
- the detectable label is a combination of an unlabeled primary antibody with a directly labeled secondary antibody specific for the primary antibody.
- probe DNA may be in solution or immobilized to any solid support and may be immobilized either before or after reaction with RecA and target DNA.
- the single DNA D-loop structure may be further stabilized by the addition, before step (d) above of the single strand DNA binding (SSB) protein (Chase et al,
- stability of the three stranded structure can also be enhanced by utilizing a DNA oligonucleotide complementary to the opposite strand of the target DNA to which the probe or probes are complementary.
- the oligonucleotide must contain a nucleotide at the site of the mutation or SNP which is not complementary to any allele of the mutation or SNP.
- the present invention also provides a kit useful for detecting a one or more mutations or polymorphisms in a DNA sample or for detecting a specific sequence in a test DNA sample, the kit being adapted to receive therein one or more containers, the kit comprising:
- a third container or plurality of containers containing buffers and reagent or reagents including dNTPs and a DNA polymerase capable of extending DNA probes when the probes are annealed to target DNA.
- kits useful for detecting a specific mutation or polymorphism or a specific sequence in a DNA sample the kit being adapted to receive therein one or more containers, the kit comprising:
- a second container or plurality of containers containing buffers and reagent or reagents including dNTPs and a DNA polymerase capable of extending DNA probes when the probes are annealed to the target DNA.
- Figures 1 and 2 are schematic representations of the RecA/ASOE detection method.
- Figure 1 shows the RecA/ASOE method using a single allele specific probe.
- the oligonucleotide "probe” is mixed with RecA protein.
- RecA coats the probe to form a "RecA filament.”
- RecA filament is added to target DNA and allowed to perform homology searching and to form a triple stranded or "D-loop" structure.
- a DNA polymerase is added along with dNPTs. If the probe is complementary to the SNP, mutation or specific sequence, i.e., the 3' end of the probe is base paired, the polymerase will extent the probe by adding nucleotides to its 3' end. Cycling involves displacement of the original oligonucleotide probe, either before or because of a second round of homology searching by a RecA filament.
- FIG. 2 shows the RecA/ASOE method employing a pair of single stranded probes, i.e. , the double D-loop method.
- Oligonucleotide probes are mixed with RecA protein.
- RecA coats the probes to form RecA filaments.
- the RecA filaments are added to target DNA and allowed to perform homology searching. If the 3' ends of the probes are complementary to the SNP, mutation or specific sequence, polymerase will extend them to form a four stranded or "double D-loop" structure. The stability of the double D-loop structure will normally require further homology searching to release the extended fragments, which will allow exponential signal amplification.
- the present inventor has devised a novel technology for detecting mutations or SNPs or for detecting specific sequences in dsDNA samples using RecA mediated homology searching followed by genotype or sequence specific oligonucleotide extension (RecA/ASOE).
- the method employs:
- a double-stranded target or test DNA molecule which may be any synthetic, viral, plasmid, prokaryotic or eukaryotic DNA from any source, including, but not limited to, genomic DNA, restriction digestion fragments or DNA amplified by PCR or any other means;
- ssDNA probes which might be any synthetic oligonucleotide, PCR amplicon, plasmid DNA, viral DNA, bacterial DNA or any other DNA of known sequence or of sequence complementary to the target DNA or to a portion thereof,
- E. coli RecA or a homologue thereof as defined below.
- the "RecA” or “SSB” is intended to include either the native or mutant E. coli RecA or SSB protein, or a "homologue” thereof as defined below.
- a "homologue” of RecA, SSB, etc. is a protein that has functional and, preferably, also structural similarity to its "reference" protein.
- One type of homologue is encoded by a homologous gene from another species of the same genus or even from other genera. As described below, these proteins, originally discovered in bacteria, have eukaryotic homologues in groups ranging from yeast to mammals.
- a functional homologue must possess the biochemical and biological activity of its reference protein, particularly the DNA binding selectivity or specificity so that it has the utility described herein.
- Nonlimiting examples of improvements include a RecA homologue that binds to shorter DNA molecules or an SSB homologue with higher binding affinity for ssDNA.
- "Homologues" is also intended to include those proteins which have been altered by mutagenesis or recombination that have been performed to improve the protein's desired function.
- Mutagenesis of a protein gene is generally accomplished in vivo by cloning the gene into bacterial vectors and duplicating it in cells under mutagenic conditions, e.g., in the presence of mutagenic nucleotide analogs and/or under conditions in which mismatch repair is deficient.
- Mutagenesis in vitro also well-known in the art, generally employs error- prone PCR wherein the desired gene is amplified under conditions (nucleotide analogues, biased triphosphate pools, etc.) that favor misincorporation by the PCR polymerase. PCR products are then cloned into expression vectors and the resulting proteins examined for function in bacterial cells.
- Recombination generally involves mixing homologous genes from different species, allowing them to recombine, frequently under mutagenic conditions, and selecting or screening for improved function of the proteins from the recombined genes. This recombination may be accomplished in vivo, most commonly in bacterial cells under mismatch repair-deficient conditions which allow recombination between diverged sequences and also increase the generation of mutations. Radman et al. have developed such methods of protein "evolution" (U.S. Pats. 5,912,119 and 5,965,415). In addition, Stemmer and colleagues have devised methods for both in vivo and in vitro recombination of diverged sequences to create "improved" proteins.
- a preferred homologue of an E. coli RecA protein or an E. coli SSB protein has (a) the functional activity of native E. coli RecA or SSB and also preferably shares (b) a sequence similarity to the native E.
- At least 65 RecA genes from different bacteria have been cloned and sequenced (Sandier, SJ, et al, Nucl Acids Res 2 ⁇ :2125-2132 (1996); Roca, Al, et al, CritRev Biochem Mol Biol 25:415-456 (1990); ⁇ isen, JA, J. Mol. Evol ⁇ 7:1105-1123 (1995); Lloyd, AT, et al., J. Mol. Evol. 37:399-407 (1993)).
- RecA homologues known as RadA proteins (and genes), have been identified in three archaean species (Sandier et al, supra;; Seitz, ⁇ M, et al, Genes Dev. 72:1248-1253 (1998)). Eukaryotic homologues of RecA have been identified in every eukaryotic species examined; the prototype eukaryotic RecA homologue is the yeast Rad51 protein (Seitz et al, supra; Bianco, PR, et al, Frontiers Biosci. 3:570-603 (1998)). Therefore, any homologue of E. coli RecA which, like the E.
- RecA functions in vitro, forming a three stranded structure involving oligonucleotides along sequence stretches as short as 15 nucleotides (Ferrin et al, 1991, supra).
- the present system employs:
- Probe specificity derives from probe sequence.
- An oligonucleotide probe is designed to be complementary to the target DNA in the specific sequence of interest or to have its 3' end complementary to a specific allele of a mutation or SNP.
- Formation or stabilization of the D-loop formed by the RecA filaments and target DNA may be further enhanced by the addition of single strand binding (SSB) protein from E. coli or a homologue of SSB or by allowing double D-loop formation using an oligonucleotide complementary to the strand opposite that to which the oligonucleotide probe is complementary.
- SSB single strand binding
- the stabilizing oligonucleotide When using an oligonucleotide in mutation or SNP detection to stabilize a single D-loop by forming a double D-loop, the stabilizing oligonucleotide must either terminate before the SNP or mutation site or must have a nucleotide at the site of the mutation or SNP that is not complementary to any allele of the mutation or SNP to prevent probe annealing and extension. [0047] In the RecA/ASOE method, detection of mutations, SNPs and specific sequences is accomplished by detecting the covalent linkage (by DNA polymerase) of dNTPs to the oligonucleotide probe molecule.
- the DNA oligonucleotide probe may be of any length but is preferably a synthetic oligonucleotide, of about 30-60 bases in length and is specific for a genetic region that is being examined for the presence of a mutation or SNP or for its presence in a particular target DNA sample.
- the target DNA may be of any length (up to an entire chromosome) and can be either genomic or plasmid DNA or a PCR amplicon.
- the oligonucleotides and/or dNTPs can be directly labeled with fluorophores or fluorescent labels, including, but not limited to, Fluorescein (and derivatives), 6-Fam, Hex, Tetramethylrhodamine, cyanine-5, CY-3, allophycocyanin, Lucifer yellow CF, Texas Red, Rhodamine, Tamra, Rox, Dabcyl. '
- RecA filament formation can be accomplished, for example, in a Tris-HCl or Tris-acetate buffer, (20-40 mM, pH 7.4-7.9) with MgC12 or Mg acetate (1-4 mM), dithiothreitol (0.2-0.5 mM), and ATP or ATP[(-S] (0.3-1.5 mM). If ATP is used, an ATP regenerating system comprising phosphocreatine and creatine kinase may be included. RecA and oligonucleotide are generally added at a molar ratio of about 0.1-3 (RecA to nucleotides). If the probe is double- stranded, it must first be denatured before RecA coating.
- D-loop or triple strand structure formation involves adding RecA filaments to dsDNA and incubating, preferably at 37°C, for about 15 min - 2 hrs. It is also possible to form RecA filaments and do homology searching in a single reaction vessel, i.e., to mix RecA with oligonucleotides and dsDNA at the same time. See, for example, Rigas et al, supra; Honigberg, SM, et al, Proc Natl Acad Sci USA 83:9586-9590 (1986); any of the Ferrin et al. publications ( supra).
- Oligonucleotide extension can be accomplished by any primer dependent DNA polymerase (see Goelet, P et al, US Patents 5,888,819 and 6,004,744)
- the present system employs:
- DNA polymerase and dNTPs for extension of annealed oligonucleotides, all or some of which dNTPs may be detectably labeled or contain adducts to allow immobilization.
- the target DNA may be of any length (up to an entire chromosome) and can be either genomic or plasmid DNA or a PCR amplicon.
- the detectably labeled oligonucleotides can be directly labeled with fluorophores or fluorescent labels, including, but not limited to, Fluorescein (and derivatives), 6-Fam, Hex, Tetramethylrhodamine, cyanine-5, CY-3, allophycocyanin, Lucifer yellow CF, Texas Red, Rhodamine, Tamra, Rox, Dabcyl. They may also be labeled with radioactive labels, digoxigenin, chemiluminescent labels or colorimetric labels.
- RecA filament formation can be accomplished, for example, in a Tris-HCl or Tris- acetate buffer, (20-40 mM, pH 7.4-7.9) with MgC12 or Mg acetate (1-4 mM), dithiotlireitol (0.2- 0.5 mM), and ATP or ATP[(-S] (0.3-1.5 mM). If ATP is used, an ATP regenerating system comprising phosphocreatine and creatine kinase may be included. RecA and oligonucleotide are generally added at a molar ratio of 0.1-3 (RecA to nucleotides).
- oligonucleotide If the oligonucleotide is double- stranded, it must first be denatured before RecA coating. Incubation is at room temperature or, preferably, 37°C, for 5-30 min. D-loop or triple strand structure formation involves adding RecA filaments to dsDNA and incubating, preferably at 37°C, for about 15 min - 2 hrs. It is also possible to form RecA filaments and do homology searching in a single reaction vessel, i.e., to mix RecA with oligonucleotides and dsDNA at the same time. See, for example, Rigas et al, supra; Honigberg, SM, et a , Proc Natl Acad Sci USA 83:9586-9590 (1986); any of the Ferrin et al publications ( supra).
- Oligonucleotide extension can be detected by immobilizing the extended, detectably labeled oligonucleotides in an extension dependent fashion.
- a dNTP may be bound to biotin to allow their immobilization to avidin or streptavidin coated surfaces, including but not limited to microtiter plates, magnetic beads and microspheres (beads).
- immobilization may be accomplished by allowing extended oligonucleotides to anneal to immobilized single stranded oligonucleotides (immobilization oligonucleotides) complementary to the extended sequence, i.e., not to the probe.
- immobilization oligonucleotides complementary to the extended sequence, i.e., not to the probe.
- immobilization of the oligonucleotides may be to microtiter plates, magnetic beads, beads suitable for detection via flow cytometry, microarrays or any other solid surface. Detection may be via any the methods well known in the art including, but not limited to, plate readers, flow cytometers and microarray readers.
- RecA is mixed with a synthetic oligonucleotide, of any length, but preferably of 30 - 60 bases in length, under conditions that allow formation of RecA filament. Filament formation may occur before or after addition of oligonucleotide to double-stranded target DNA.
- Target DNA may be any dsDNA including, but not limited to, genomic DNA of any species, viral DNA, plasmid DNA, PCR amplicons, restriction fragments, or cloned DNA.
- the oligonucleotide is selected to be complementary to a specific region of the target DNA such that the 3' end of the oligonucleotide complementary to one allele of the mutation or SNP to be detected.
- Conditions are established, following formation of the RecA filament or following mixing of the RecA filament with target DNA, such that RecA filament is allowed to conduct a homology search on the target DNA.
- a triple stranded structure will be formed.
- This triple stranded structure will contain a 3' end (of the oligonucleotide) suitable for extension by DNA polymerase.
- the DNA polymerase may be any polymerase and is not required to be thermostable.
- Detection of extended oligonucleotides is accomplished by separating the extended oligonucleotides from oligonucleotides that have not been extended.
- adduct present in the dNTPs used for extension such as biotin
- the complementary oligonucleotide method of immobilization allows multiplexing of the extension reaction to examine multiple sites in a single target DNA sample and yet score them separately.
- multiplexing can be accomplished by adding 5' oligonucleotide "tails" to the extension oligonucleotides and detectably labeled dNTPs.
- tails attached to extension oligonucleotides with 3' ends complementary to different alleles will allow extension products to be scored independently.
- Detection of label may be accomplished by a variety of methods including, but not limited to, plate readers capable of detecting visible or fluorescent signals, microarray readers and flow cytometers.
- This technology is ideally suited to multiplexing wherein several sites in a single sample of genomic, plasmid or amplified DNA are interrogated simultaneously.
- specific probes complementary to each allele of a mutation or SNP are designed with distinguishable labels and are used with unlabeled dNTPs or the extension oligonucleotides are designed with specific oligonucleotide tails and are used with labeled dNTPs.
- Extended oligonucleotides are specifically immobilized by use of immobilization oligonucleotides complementary to the extended sequence of each probe or to the specific oligonucleotide tails, respectively.
- RecA/ASOE SNP SNP, mutation and specific sequence detection technologies
- the precision of RecA mediated homology searching allows the extremely accurate detection of infectious agents in samples with vast excesses of heterologous DNA.
- Perhaps the most important distinguishing advantage of the present invention is its complete independence from DNA amplification (i.e., PCR).
- kits useful for practicing the methods described herein.
- kits will contain a reagent combination comprising the essential elements required to conduct an assay according to the methods disclosed herein.
- the reagent system is presented in a commercially packaged form, as a composition or admixture where the compatibility of the reagents will allow, in a test device configuration, or more typically as a test kit, i.e., a packaged combination of one or more containers, devices, or the like holding the necessary reagents, and usually including written instructions for the performance of assays.
- the kit of the present invention may include any configurations and compositions for performing the various assay formats described herein.
- Kits containing RecA, oligonucleotides and, where applicable, reagents for detection of fluorescent, chemiluminescent, radioactive or colorimetric signals are within the scope of this invention.
- a kit of this invention designed to allow detection of specific mutations and/or polymorphisms or mutations and/or in specific sequences of target DNA includes oligonucleotides or other probes specific for (a) selected mutations and/or (b) SNPs, or (c) specific region or regions of target DNA.
- the probes may be labeled as described above.
- the kits also include a plurality of containers of appropriate buffers and reagents.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04718028A EP1613768A4 (en) | 2003-03-11 | 2004-03-05 | Reca-assisted allele specific oligonucleotide extension method |
AU2004219662A AU2004219662A1 (en) | 2003-03-11 | 2004-03-05 | RecA-assisted allele specific oligonucleotide extension method |
CA002518452A CA2518452A1 (en) | 2003-03-11 | 2004-03-05 | Reca-assisted allele specific oligonucleotide extension method for detecting mutations, snps and specific sequences |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45364003P | 2003-03-11 | 2003-03-11 | |
US60/453,640 | 2003-03-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004081224A2 true WO2004081224A2 (en) | 2004-09-23 |
WO2004081224A3 WO2004081224A3 (en) | 2005-04-07 |
Family
ID=32990801
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/006704 WO2004081224A2 (en) | 2003-03-11 | 2004-03-05 | Reca-assisted allele specific oligonucleotide extension method |
Country Status (5)
Country | Link |
---|---|
US (1) | US20040224336A1 (en) |
EP (1) | EP1613768A4 (en) |
AU (1) | AU2004219662A1 (en) |
CA (1) | CA2518452A1 (en) |
WO (1) | WO2004081224A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1932925A1 (en) * | 2006-12-04 | 2008-06-18 | FUJIFILM Corporation | Method for detecting mutation of nucleic acid using single-stranded DNA-binding protein |
CN106701738A (en) * | 2016-11-10 | 2017-05-24 | 中国科学院成都生物研究所 | Methods of isothermally unlocking double-stranded DNA and preparing single stranded DNA |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE400663T1 (en) * | 2002-02-21 | 2008-07-15 | Asm Scient Inc | RECOMBINASE-POLYMERASE AMPLIFICATION |
US7399590B2 (en) | 2002-02-21 | 2008-07-15 | Asm Scientific, Inc. | Recombinase polymerase amplification |
US8030000B2 (en) | 2002-02-21 | 2011-10-04 | Alere San Diego, Inc. | Recombinase polymerase amplification |
US7563600B2 (en) | 2002-09-12 | 2009-07-21 | Combimatrix Corporation | Microarray synthesis and assembly of gene-length polynucleotides |
US20060281113A1 (en) * | 2005-05-18 | 2006-12-14 | George Church | Accessible polynucleotide libraries and methods of use thereof |
JP5027126B2 (en) | 2005-07-25 | 2012-09-19 | アリーア サン ディエゴ, インコーポレイテッド | Method for multiplexing recombinase polymerase amplification |
US7919583B2 (en) * | 2005-08-08 | 2011-04-05 | Discovery Genomics, Inc. | Integration-site directed vector systems |
CA2650993C (en) * | 2006-05-04 | 2015-06-16 | Asm Scientific, Inc. | Recombinase polymerase amplification |
WO2009052214A2 (en) * | 2007-10-15 | 2009-04-23 | Complete Genomics, Inc. | Sequence analysis using decorated nucleic acids |
WO2009062152A1 (en) * | 2007-11-09 | 2009-05-14 | Washington University In St. Louis | Methods for measuring the metabolism of cns derived biomolecules in vivo |
WO2010011506A2 (en) * | 2008-07-23 | 2010-01-28 | The Washington University | Risk factors and a therapeutic target for neurodegenerative disorders |
US9469867B2 (en) * | 2009-05-20 | 2016-10-18 | Alere San Diego, Inc. | DNA glycosylase/lyase and AP endonuclease substrates |
EP2438196B1 (en) | 2009-06-05 | 2016-12-21 | Alere San Diego, Inc. | Recombinase polymerase amplification reagents and kits |
CN105907846A (en) | 2011-04-07 | 2016-08-31 | 美艾利尔圣地亚哥有限公司 | Monitoring recombinase polymerase amplification mixtures |
WO2014182634A1 (en) * | 2013-05-06 | 2014-11-13 | Two Pore Guys, Inc. | A method of biological target detection using a nanopore and a fusion protein binding agent |
KR102245192B1 (en) | 2013-05-06 | 2021-04-29 | 온테라 인크. | Target detection with nanopore |
WO2014210219A1 (en) * | 2013-06-25 | 2014-12-31 | Two Pore Guys, Inc. | Multiplexed biomarker quantitation by nanopore analysis of biomarker-polymer complexes |
WO2016054247A1 (en) | 2014-09-30 | 2016-04-07 | Washington University | Tau kinetic measurements |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE61148B1 (en) * | 1988-03-10 | 1994-10-05 | Ici Plc | Method of detecting nucleotide sequences |
US5273881A (en) * | 1990-05-07 | 1993-12-28 | Daikin Industries, Ltd. | Diagnostic applications of double D-loop formation |
ATE153707T1 (en) * | 1990-05-07 | 1997-06-15 | Daikin Ind Ltd | DIAGNOSTIC APPLICATIONS OF DOUBLE D-LOOPS FORMATION. |
WO1995018236A1 (en) * | 1993-12-28 | 1995-07-06 | Daikin Industries, Ltd. | IN-SITU HYBRIDIZATION METHOD USING RecA PROTEIN AND RecA PROTEIN HAVING MARKER OR LIGAND FOR USE IN SAID METHOD |
IL135852A0 (en) * | 1997-10-28 | 2001-05-20 | Univ California | A method for detecting dna base mismatch |
EP1368501A4 (en) * | 2001-02-21 | 2005-01-19 | Gene Check Inc | Mutation detection using muts and reca |
-
2004
- 2004-03-05 EP EP04718028A patent/EP1613768A4/en not_active Withdrawn
- 2004-03-05 CA CA002518452A patent/CA2518452A1/en not_active Abandoned
- 2004-03-05 WO PCT/US2004/006704 patent/WO2004081224A2/en active Application Filing
- 2004-03-05 AU AU2004219662A patent/AU2004219662A1/en not_active Abandoned
- 2004-03-05 US US10/792,785 patent/US20040224336A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
See references of EP1613768A4 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1932925A1 (en) * | 2006-12-04 | 2008-06-18 | FUJIFILM Corporation | Method for detecting mutation of nucleic acid using single-stranded DNA-binding protein |
CN106701738A (en) * | 2016-11-10 | 2017-05-24 | 中国科学院成都生物研究所 | Methods of isothermally unlocking double-stranded DNA and preparing single stranded DNA |
CN106701738B (en) * | 2016-11-10 | 2020-05-08 | 中国科学院成都生物研究所 | Method for isothermal unwinding of double-stranded DNA and preparation of single-stranded DNA |
Also Published As
Publication number | Publication date |
---|---|
WO2004081224A3 (en) | 2005-04-07 |
EP1613768A4 (en) | 2006-05-31 |
US20040224336A1 (en) | 2004-11-11 |
AU2004219662A1 (en) | 2004-09-23 |
EP1613768A2 (en) | 2006-01-11 |
CA2518452A1 (en) | 2004-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002311761B2 (en) | Mutation detection using MutS and RecA | |
US20240368682A1 (en) | Systems and methods for clonal replication and amplification of nucleic acid molecules for genomic and therapeutic applications | |
US20040224336A1 (en) | RecA-assisted specific oligonucleotide extension method for detecting mutations, SNPs and specific sequences | |
CN105934523B (en) | Multiplex Detection of Nucleic Acids | |
US6238866B1 (en) | Detector for nucleic acid typing and methods of using the same | |
US7090975B2 (en) | Pyrophosphorolysis and incorporation of nucleotide method for nucleic acid detection | |
AU2002311761A1 (en) | Mutation detection using MutS and RecA | |
WO2006113590A2 (en) | Flow-cytometric heteroduplex analysis for detection of genetic alterations | |
JP2007525963A (en) | Methods and compositions for whole genome amplification and genotyping | |
CN1665938B (en) | Methods of detecting sequence differences | |
US7244562B2 (en) | RecA assisted detection of mutations, single nucleotide polymorphisms and specific sequences | |
CN109563530B (en) | RNase H mutants in emulsion | |
CN105793435A (en) | Multiplex probes | |
US7262032B2 (en) | Allele-specific mutation detection assay using an enzyme-disabling agent | |
US20030154033A1 (en) | Methods and compositions for detecting differences between nucleic acids | |
AU2003247603A1 (en) | Methods and compositions for monitoring primer extension and polymorphism detection reactions | |
US20140349879A1 (en) | Method for detecting nucleotide mutation, and detection kit | |
AU2002359334A1 (en) | RecA assisted detection of mutations, single nucleotide polymorphisms and specific sequences | |
US20100196893A1 (en) | Method for genotyping DNA tandem repeat sequences | |
Nolan et al. | SNP scoring for drug discovery applications | |
CN119137285A (en) | Method for detecting target nucleic acid sequences in a single reaction vessel | |
Nolan et al. | Los Alamos National Laboratory Los Alamos, New Mexico | |
JP2002223761A (en) | Method for detecting target nucleic acid and reagent therefor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004219662 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2518452 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2004219662 Country of ref document: AU Date of ref document: 20040305 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004219662 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004718028 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004718028 Country of ref document: EP |